LONDON (Alliance News) - Redx Pharma PLC said Monday it has reached the pre-clinical proof of concept stage with its advanced oncology compound with the potential to treat cancers including pancreatic, breast, head and neck cancer.
The small molecule inhibitor targets the Wnt pathway, Redx said, which is implicated in the maintenance of cancer stem cells in multiple cancer types.
This is its fifth programme to have reached the pre-clinical proof of concept stage.
"We're very pleased to have reached pre-clinical proof of concept with this very promising program. The cancers it has the potential to tackle are some of the most hard-to-treat," said Chief Executive Officer Neil Murray in a statement.
Shares in Redx are trading up 2.1% at 85.75 pence Monday morning.
By Hana Stewart-Smith; hanassmith@alliancenews.com; @HanaSSAllNews
Copyright 2015 Alliance News Limited. All Rights Reserved.
